ZA964486B - Isoxazoline and isoxazole fibrinogen receptor antagonists. - Google Patents

Isoxazoline and isoxazole fibrinogen receptor antagonists.

Info

Publication number
ZA964486B
ZA964486B ZA9604486A ZA964486A ZA964486B ZA 964486 B ZA964486 B ZA 964486B ZA 9604486 A ZA9604486 A ZA 9604486A ZA 964486 A ZA964486 A ZA 964486A ZA 964486 B ZA964486 B ZA 964486B
Authority
ZA
South Africa
Prior art keywords
compounds
isoxazoline
fibrinogen receptor
receptor antagonists
isoxazole fibrinogen
Prior art date
Application number
ZA9604486A
Other languages
English (en)
Inventor
John Wityak
Thais Motria Sielecki-Dzurdz
William Frank Degrado
Douglas Guy Batt
Munir Alwan Hussain
Chu-Biao Xue
Richard Eric Olson
Gary Avonn Cain
Donald Pinto
Shaker Ahmed Mousa
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of ZA964486B publication Critical patent/ZA964486B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA9604486A 1995-05-31 1996-05-31 Isoxazoline and isoxazole fibrinogen receptor antagonists. ZA964486B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/455,436 US5849736A (en) 1993-11-24 1995-05-31 Isoxazoline and isoxazole fibrinogen receptor antagonists

Publications (1)

Publication Number Publication Date
ZA964486B true ZA964486B (en) 1997-12-01

Family

ID=23808800

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9604486A ZA964486B (en) 1995-05-31 1996-05-31 Isoxazoline and isoxazole fibrinogen receptor antagonists.

Country Status (26)

Country Link
US (2) US5849736A (cs)
EP (1) EP0832076B1 (cs)
JP (1) JPH11504651A (cs)
KR (1) KR19990022198A (cs)
CN (1) CN1202893A (cs)
AT (1) ATE245150T1 (cs)
AU (1) AU723577B2 (cs)
BR (1) BR9609151A (cs)
CA (1) CA2222147A1 (cs)
CZ (1) CZ374397A3 (cs)
DE (1) DE69629116T2 (cs)
EA (1) EA000924B1 (cs)
EE (1) EE9700312A (cs)
ES (1) ES2198483T3 (cs)
HU (1) HUP9900102A3 (cs)
IL (1) IL118262A (cs)
LT (1) LT4416B (cs)
LV (1) LV12046B (cs)
NZ (1) NZ309944A (cs)
PL (1) PL323835A1 (cs)
RO (1) RO117324B1 (cs)
SI (1) SI9620071A (cs)
SK (1) SK162097A3 (cs)
TW (1) TW454007B (cs)
WO (1) WO1996038426A1 (cs)
ZA (1) ZA964486B (cs)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ320963A (en) * 1995-09-29 1999-08-30 Lilly Co Eli Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
EP0946528B1 (en) * 1996-12-23 2003-04-09 Bristol-Myers Squibb Pharma Company OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
US6022977A (en) * 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
WO1998056407A2 (en) * 1997-06-10 1998-12-17 Regents Of The University Of Minnesota Fibronectin antagonists as therapeutic agents and broad-spectrum enhancers of antibiotic therapy
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
EE9900584A (et) * 1997-06-19 2000-08-15 Dupont Pharmaceuticals Company Neutraalse P1 spetsiifilisusrühmaga faktori Xa inhibiitorid
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
ZA988735B (en) 1997-10-06 2000-03-23 Du Pont Pharm Co An efficient method for the conversion of nitriles to amidines.
JP2002508323A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
ZA99168B (en) * 1998-01-16 2000-07-11 Du Pont Pharm Co Pharmaceutical formulations and processes for their preparation.
ES2230841T3 (es) 1998-03-27 2005-05-01 Bristol-Myers Squibb Pharma Company Pirazolinas y triazolinas disustituidas como inhibidores del factor xa.
CA2333647A1 (en) 1998-06-29 2000-01-06 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
WO2000008001A1 (en) 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
AU763460B2 (en) 1998-10-09 2003-07-24 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
CA2345210A1 (en) * 1998-11-18 2000-05-25 Prabhakar Kondaji Judhav Novel isoxazoline fibrinogen receptor antagonists
US6319937B1 (en) 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
CA2368630A1 (en) 1999-04-02 2000-10-12 Ruth R. Wexler Aryl sulfonyls as factor xa inhibitors
IL147495A0 (en) * 1999-07-28 2002-08-14 Aventis Pharm Prod Inc Substituted oxoazaheterocycclyl compounds
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
UY26780A1 (es) * 2000-06-15 2002-01-31 Pharmacia Corp Cicloalquil avb3 antagonistas
PE20020382A1 (es) * 2000-06-15 2002-05-10 Pharmacia Corp Derivados de acido heteroarilalcanoico como antagonistas de la integrina
US6906046B2 (en) 2000-12-22 2005-06-14 Celltech R & D Inc. Pharmaceutical uses and synthesis of benzobicyclooctanes
EP1411930B1 (en) * 2001-06-08 2013-01-16 Cytokine Pharmasciences, Inc. Isoxazoline compounds having mif antagonist activity
US20040043988A1 (en) * 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
KR20100054884A (ko) 2001-10-22 2010-05-25 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
US20030206906A1 (en) * 2001-11-26 2003-11-06 Genentech, Inc. Catheter composition and uses thereof
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
MXPA05006727A (es) * 2002-12-20 2005-09-08 Pharmacia Corp Acidos heteroarilalcanoicos como antagonistas de receptor de integrina.
BR0316875A (pt) * 2002-12-20 2005-10-25 Pharmacia Corp Compostos de pirazol como derivados antagonistas receptores da integrina, sua composição farmacêutica e respectivo uso
MXPA05006587A (es) * 2002-12-20 2005-12-14 Pharmacia Corp Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
PL377550A1 (pl) * 2002-12-25 2006-02-06 Daiichi Pharmaceutical Co., Ltd. Pochodne diamin
US7250415B2 (en) * 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
JP4883296B2 (ja) 2004-03-05 2012-02-22 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
AU2005228417A1 (en) * 2004-03-26 2005-10-13 Cytokine Pharmasciences, Inc. Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
MXPA06014754A (es) * 2004-06-17 2007-06-22 Infinity Pharmaceuticals Inc Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace.
AU2006224777B2 (en) * 2005-03-15 2012-08-30 Ganial Immunotherapeutics Inc. Compounds having immunomodulator activity
DE102005044813A1 (de) * 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
CA2621228C (en) 2005-09-02 2014-05-27 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pesticide
EP1945262A2 (en) * 2005-10-20 2008-07-23 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
PT1984344E (pt) 2005-12-29 2012-12-21 Lexicon Pharmaceuticals Inc Derivados de aminoácidos multicíclicos e métodos para a sua utilização
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses
WO2008154528A2 (en) 2007-06-13 2008-12-18 E. I. Du Pont De Nemours And Company Isoxazoline insecticides
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
WO2009003075A1 (en) 2007-06-27 2008-12-31 E.I. Du Pont De Nemours And Company Animal pest control method
TWI600639B (zh) 2007-08-17 2017-10-01 杜邦股份有限公司 製備５-鹵烷基-４，５-二氫異唑衍生物之化合物
US8367584B2 (en) 2007-10-03 2013-02-05 E.I. Du Pont De Nemours And Company Naphthalene isoxazoline compounds for control of invertebrate pests
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
TW201444787A (zh) 2008-04-09 2014-12-01 Du Pont 製備３-三氟甲基查耳酮（ｃｈａｌｃｏｎｅ）之方法
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2011066482A2 (en) * 2009-11-25 2011-06-03 Cytokine Pharmasciences, Inc. Chiral synthesis of isoxazolines, isoxazoline compounds, and uses thereof
PH12012502333A1 (en) 2010-05-27 2015-02-04 Corteva Agriscience Llc Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide
US20150064221A1 (en) 2012-04-17 2015-03-05 Niranjan Y. Sardesai Compounds having immunomudulator activity
KR102506324B1 (ko) 2016-11-08 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 시클로부탄- 및 아제티딘-함유 모노 및 스피로시클릭 화합물
KR102510858B1 (ko) * 2016-11-08 2023-03-15 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 아졸 아미드 및 아민
CA3042707A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as .alpha.v integrin inhibitors
AU2017359027A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Indazole derivatives as αV integrin antagonists
BR112019009293A2 (pt) 2016-11-08 2019-07-30 Bristol-Myers Squibb Company pirrol amidas como inibidores de integrina alfa v
US11292802B2 (en) 2017-11-07 2022-04-05 Bristol-Myers Squibb Company Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors
US10759756B2 (en) * 2018-04-12 2020-09-01 Morphic Therapeutic, Inc. Antagonists of human integrin α4β7
PE20221829A1 (es) 2019-10-16 2022-11-29 Morphic Therapeutic Inc Inhibicion de integrina alfa4 beta7 humana
CN111323570B (zh) * 2020-03-25 2021-11-05 天津市宝坻区人民医院 基于血栓弹力图的阿司匹林药物抵抗检测方法
CN117940407A (zh) * 2021-08-13 2024-04-26 Lapix生物治疗股份有限公司 降低免疫不耐受和治疗自身免疫病症的组合物和方法
EP4509511A1 (en) 2023-08-17 2025-02-19 Bayer Aktiengesellschaft Substituted spiro-isoxazolinyl lactams, salts thereof and their use as herbicidally active substances

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2811190A1 (de) * 1978-03-15 1979-09-20 Bayer Ag Verfahren zur herstellung von 2-(2,2-dimethyl-3-buten-1-yl)-2-oxazolinen
DE2852924A1 (de) * 1978-12-07 1980-06-26 Bayer Ag Substituierte spiro-derivate von 3- (3,5-dihalogenphenyl)-oxazolidin-2,4-dionen (thion-onen), verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2037153A1 (en) * 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
IL99538A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
DE4107857A1 (de) * 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
UA39849C2 (uk) * 1991-03-26 2001-07-16 Ф.Хоффманн-Ля Рош Аг ПОХІДНІ N-АЦИЛ-<font face="Symbol">a</font>-АМІНОКИСЛОТИ АБО ЇХ ФІЗІОЛОГІЧНО ПРИЙНЯТНІ СОЛІ, ПРОСТІ АБО СКЛАДНІ ЕФІРИ, АМІДИ АБО ЇХ ГІДРАТИ ЯК ФАРМАЦЕВТИЧНО АКТИВНІ РЕЧОВИНИ
US5321034A (en) * 1991-05-07 1994-06-14 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1992019595A1 (en) * 1991-05-07 1992-11-12 Merck & Co., Inc. Fibrinogen receptor antagonists
US5220050A (en) * 1991-05-17 1993-06-15 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4126277A1 (de) * 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4207254A1 (de) * 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4212304A1 (de) * 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
DE4213634A1 (de) * 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4213931A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DK0649843T3 (da) * 1992-07-15 2000-10-09 Taisho Pharmaceutical Co Ltd Thiazolinderivater
US5478945A (en) * 1992-07-15 1995-12-26 Taisho Pharmaceutical Co., Ltd. Thiazoline derivatives
DE4224414A1 (de) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
JP3322878B2 (ja) * 1992-10-14 2002-09-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
US5559127A (en) * 1992-10-14 1996-09-24 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2150550A1 (en) * 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
DE4302051A1 (de) * 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332168A1 (de) * 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
HUT71796A (en) * 1993-02-22 1996-02-28 Merck & Co Inc Condensed cyclic compounds with nitrogen heteroatoms and pharmaceutical compositions of fibrinogen receptor antagonistic activity containing them
US5334596A (en) * 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
US5397791A (en) * 1993-08-09 1995-03-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5430043A (en) * 1993-08-24 1995-07-04 G. D. Searle & Co. Platelet aggregation inhibitors
DK0730590T3 (da) * 1993-11-24 2001-03-19 Du Pont Pharm Co Isoxazolin og isozazol fibrinogenreceptorantagonister
AU677481B2 (en) * 1993-11-24 1997-04-24 Du Pont Pharmaceuticals Company Isoxazoline compounds useful as fibrinogen receptor antagonists
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists

Also Published As

Publication number Publication date
LT97182A (en) 1998-07-27
EP0832076B1 (en) 2003-07-16
HUP9900102A2 (hu) 1999-05-28
ES2198483T3 (es) 2004-02-01
BR9609151A (pt) 1999-06-29
DE69629116D1 (de) 2003-08-21
PL323835A1 (en) 1998-04-27
AU723577B2 (en) 2000-08-31
NZ309944A (en) 1999-10-28
EA199700452A1 (ru) 1998-10-29
IL118262A0 (en) 1996-09-12
RO117324B1 (ro) 2002-01-30
US5849736A (en) 1998-12-15
CA2222147A1 (en) 1996-12-05
KR19990022198A (ko) 1999-03-25
IL118262A (en) 2003-02-12
SK162097A3 (en) 1999-04-13
US6114328A (en) 2000-09-05
WO1996038426A1 (en) 1996-12-05
LV12046A (lv) 1998-05-20
LV12046B (en) 1998-09-20
LT4416B (lt) 1998-12-28
JPH11504651A (ja) 1999-04-27
EA000924B1 (ru) 2000-06-26
SI9620071A (sl) 1998-12-31
EE9700312A (et) 1998-06-15
TW454007B (en) 2001-09-11
DE69629116T2 (de) 2004-04-08
EP0832076A1 (en) 1998-04-01
CZ374397A3 (cs) 1998-12-16
ATE245150T1 (de) 2003-08-15
CN1202893A (zh) 1998-12-23
HUP9900102A3 (en) 2001-11-28
AU6024396A (en) 1996-12-18

Similar Documents

Publication Publication Date Title
ZA964486B (en) Isoxazoline and isoxazole fibrinogen receptor antagonists.
EP0970950A3 (en) Novel isoxazoline and isoxazole fibrinogen receptor antagonists
DK0730589T3 (da) Isoxazolinforbindelser, der er nyttige som fibrinogenreceptorantagonister
EP0874629A4 (en) ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE AS FACTOR Xa INHIBITORS
TW363064B (en) Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
EP1129089A4 (en) SPIRO-INDOLE AS Y5 RECEPTOR ANTAGONISTS
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
EP0080104A3 (en) 3-(4-piperidyl)-1,2-benzisoxazoles, intermediates and process for the preparation thereof, a pharmaceutical composition comprising the same and their use as medicament
ATE178614T1 (de) Zyklische verbindungen zur verwendung als inhibitoren des glycoprotein iib/iiia
ES2124905T3 (es) Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.
WO2000029406A3 (en) Novel isoxazoline fibrinogen receptor antagonists
DK58291D0 (da) Krystalinsk stof og dets fremstilling
WO2005035495A3 (en) Fibrinogen receptor antagonists and their use
MX9709081A (es) Nuevos antagonistas del receptor fibrinogeno de isoxazolina e isoxazol.
IL66868A0 (en) 6-fluoro-3-(3-(1-heterocyclo) propyl)-1,2-benzisoxazoles,a process for their preparation,pharmaceutical compositions thereof and their use as medicaments
DE50005213D1 (de) Endoparasitizide synergistische kombination enthaltend cyclische depsipeptide und piperazine
FR2703262B1 (fr) Mélanges gazeux.
BR9815399A (pt) Processo para formação de um composto, processo para preparação do composto e composto